Biologics

Plano-based Texas Back Institute researchers are assessing the effectiveness of stem cells for revitalizing spinal tissue in a clinical trial.

A new class of clay nanoparticles can lead human mesenchymal stem cells to develop into bone or cartilage cells, Futurity reports.

SpinalCyte is a Houston-based tissue engineering company developing a spinal nucleus replacement solution using human dermal fibroblasts.

Kevin Plancher, MD, is a board-certified orthopedic surgeon and founder of Plancher Orthopaedics & Sports Medicine in New York City and Greenwich, Conn. Here are his insights on joint replacement versus growth factors and stem cell therapy for the treatment…

SpinalCyte filed an Investigational New Drug Application with the FDA to expand its study of CybroCell Human Dermal Fibroblasts for the treatment of degenerative disc disease.

The orthopedic biomaterials market is growing as the U.S. population ages, according to a Transparency Market Research report.

The American Academy of Orthopaedic Surgeons collaborated with the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases to hold a symposium Feb. 15 through Feb. 17 at Stanford (Calif.) University on optimizing the use of biologics in orthopedic surgery.

The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.

Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program…

RTI Surgical accomplished a major milestone in April.